Where Were the Women? Gender Parity in Clinical Trials

N Engl J Med. 2019 Dec 26;381(26):2491-2493. doi: 10.1056/NEJMp1913547. Epub 2019 Oct 30.

Authors

Robert H Goldstein¹, Rochelle P Walensky¹

Affiliation

¹ From the Division of Infectious Diseases, Department of Medicine (R.H.G., R.P.W.), and the Medical Practice Evaluation Center (R.P.W.), Massachusetts General Hospital, and the Harvard University Center for AIDS Research, Harvard Medical School (R.P.W.) - both in Boston.

PMID: 31665574
DOI: 10.1056/NEJMp1913547

No abstract available

MeSH terms

Adenine / analogs & derivatives*
Adenine / therapeutic use
Alanine
Anti-HIV Agents / therapeutic use*
Clinical Trials as Topic / standards
Drug Approval*
Drug Combinations
Emtricitabine / therapeutic use*
Equivalence Trials as Topic*
Female
HIV Infections / prevention & control*
Humans
Male
Pre-Exposure Prophylaxis*
Sex Factors*
Tenofovir / therapeutic use
United States
United States Food and Drug Administration

Substances

Anti-HIV Agents
Drug Combinations
Tenofovir
tenofovir alafenamide
Emtricitabine
Adenine
Alanine